نتایج جستجو برای: cytokeratin antibody

تعداد نتایج: 173745  

Journal: :Cancer research 1995
H K Parekh H Simpkins

DNA is the primary target of cis-diamminedichloroplatinum (cisplatin), but the drug also interacts with the cellular cytoskeleton composed of microtubules and intermediate filaments. It was found that the cisplatin-resistant 2008/C13* cell line contained markedly lower levels (6-fold) of cytokeratin 18, when compared to the cisplatin-sensitive 2008 cell line. Northern blot analysis revealed a m...

2017
Anna Karolina Zuk Xuesong Wen Stephen Dilworth Dong Li Lucy Ghali

The use of three dimensional in vitro systems in cancer research is a promising path for developing effective anticancer therapies. The aim of this study was to engineer a functional 3-Din vitro model of normal and cancerous cervical tissue.Normal epithelial and immortalized cervical epithelial carcinoma cell lines were used to construct 3-D artificial normal cervical and cervical cancerous tis...

Journal: :Archives of otolaryngology--head & neck surgery 2004
Marta T Becker Carol G Shores Kathy K Yu Wendell G Yarbrough

BACKGROUND The presence or absence of metastatic disease in cervical lymph nodes is the single most important determinant of therapy and prognosis for patients with head and neck squamous cell carcinoma (HNSCC). However, histologic examination fails to detect metastatic disease in a subset of neck dissection specimens. The accuracy of neck staging may be improved by the use of molecular techniq...

Journal: :Revista medica de Chile 2008
Marcelo Garrido S Pablo Ramírez V Concepción Risueño A Eric Orellana U Héctor Galindo A Manuel Alvarez Z

BACKGROUND Colorectal cancer relapses or metastasizes in 30% of cases. Cytokeratin 20 is present in 95% of colorectal tumors and their metastases and could be used as a marker to detect tumor cells. AIM To assess the usefulness and prognostic value of peripheral blood and bone marrow cytokeratin 20 determinations in patients with colorectal cancer. MATERIAL AND METHODS Blood and bone marrow...

2013
Fernando N. Aguiar Henrique N. Mendes Cinthya S. Cirqueira Carlos E. Bacchi Filomena M. Carvalho

OBJECTIVES Biological markers that predict the development of invasive breast cancer are needed to improve personalized therapy for patients diagnosed with ductal carcinoma in situ. We investigated the role of basal cytokeratin 5/6 in the risk of invasion in breast ductal carcinoma in situ. METHODS We constructed tissue microarrays using 236 ductal carcinoma in situ samples: 90 pure samples (...

Journal: :Endoscopy 2012
T Terada

of the pancreas is extremely rare [1]; only three cases have been reported in the literature [2–4]. A61-year-oldmanpresentedwith abdominal pain. Laboratory blood testing revealed hyperamylasemia (626 IU/L). Tumor marker concentrations were within normal ranges. Upper gastrointestinal endoscopy showed no significant changes, as did CT including the pancreas. Pancreatitis was suspected and the pa...

2012
T. Terada

of the pancreas is extremely rare [1]; only three cases have been reported in the literature [2–4]. A61-year-oldmanpresentedwith abdominal pain. Laboratory blood testing revealed hyperamylasemia (626 IU/L). Tumor marker concentrations were within normal ranges. Upper gastrointestinal endoscopy showed no significant changes, as did CT including the pancreas. Pancreatitis was suspected and the pa...

Journal: :Saudi medical journal 2013
Don E Asberry George A Youngberg Mousa A Al-Abbadi

Mucinous cystic neoplasms (MCN) with malignant sarcomatous stroma are rare aggressive tumors and there are few recorded cases. We report a case of MCN that had adenocarcinoma in situ and invasive adenocarcinoma with foci of sarcomatous stroma in a 40-year-old woman. Clear transition from adenocarcinoma areas into sarcomatoid foci was noted. The stromal component showed immunoreactivity for CK7 ...

Journal: :The American journal of pathology 2002
Matt van de Rijn Charles M Perou Rob Tibshirani Phillippe Haas Olli Kallioniemi Juha Kononen Joachim Torhorst Guido Sauter Markus Zuber Ossi R Köchli Frank Mross Holger Dieterich Rob Seitz Doug Ross David Botstein Pat Brown

While several prognostic factors have been identified in breast carcinoma, the clinical outcome remains hard to predict for individual patients. Better predictive markers are needed to help guide difficult treatment decisions. In a previous study of 78 breast carcinoma specimens, we noted an association between poor clinical outcome and the expression of cytokeratin 17 and/or cytokeratin 5 mRNA...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید